Tscan Therapeutics Inc (TCRX)

$9.19

+0.21

(+2.34%)

Market is closed - opens 7 PM, 21 May 2024

Insights on Tscan Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 7.21M → 566.0K (in $), with an average decrease of 92.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -19.61M → -30.14M (in $), with an average decrease of 53.7% per quarter

Performance

  • $8.79
    $9.19
    $9.19
    downward going graph

    4.41%

    Downside

    Day's Volatility :4.41%

    Upside

    0.0%

    downward going graph
  • $1.93
    $9.36
    $9.19
    downward going graph

    79.0%

    Downside

    52 Weeks Volatility :79.38%

    Upside

    1.82%

    downward going graph

Returns

PeriodTscan Therapeutics IncIndex (Russel 2000)
3 Months
21.19%
0.0%
6 Months
94.79%
0.0%
1 Year
181.5%
0.0%
3 Years
-14.48%
-19.9%

Highlights

Market Capitalization
470.5M
Book Value
$3.15
Earnings Per Share (EPS)
-1.36
Wall Street Target Price
12.67
Profit Margin
0.0%
Operating Margin TTM
-296.17%
Return On Assets TTM
-24.79%
Return On Equity TTM
-71.29%
Revenue TTM
21.0M
Revenue Per Share TTM
0.32
Quarterly Revenue Growth YOY
133.0%
Gross Profit TTM
-46.3M
EBITDA
-88.1M
Diluted Eps TTM
-1.36
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.04
EPS Estimate Next Year
-1.14
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.25

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Tscan Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 37.87%

Current $9.19
Target $12.67

Technicals Summary

Sell

Neutral

Buy

Tscan Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Tscan Therapeutics Inc
Tscan Therapeutics Inc
26.12%
94.79%
181.5%
-14.48%
-14.48%
Moderna, Inc.
Moderna, Inc.
27.23%
68.31%
4.86%
-19.93%
488.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.12%
22.54%
30.71%
91.4%
224.65%
Novo Nordisk A/s
Novo Nordisk A/s
5.29%
27.32%
54.69%
226.34%
458.15%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.32%
24.76%
30.96%
105.54%
168.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Tscan Therapeutics Inc
Tscan Therapeutics Inc
NA
NA
NA
-1.04
-0.71
-0.25
NA
3.15
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.57
28.57
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.03
46.03
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.58
28.58
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Tscan Therapeutics Inc
Tscan Therapeutics Inc
Buy
$470.5M
-14.48%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$50.8B
488.05%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$106.7B
224.65%
28.57
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$593.5B
458.15%
46.03
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$113.7B
168.64%
28.58
39.46%

Institutional Holdings

  • EcoR1 Capital, LLC

    10.44%
  • Adage Capital Partners Gp LLC

    8.15%
  • Bvf Inc

    6.24%
  • Baker Bros Advisors LP

    5.82%
  • Propel Bio Management LLC

    4.36%
  • Vanguard Group Inc

    3.73%

Company Information

harnessing novel t cell systems to extend the promise of immunotherapy

Organization
Tscan Therapeutics Inc
Employees
154
CEO
Dr. Gavin MacBeath Ph.D.
Industry
Miscellaneous

FAQs